Notizie
Healiva® acquisisce da Smith+Nephew due asset di terapia cellulare per la guarigione delle ferite
Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer
Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference
Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®
United States Ambassador Scott Miller meets the Chairman of Farma Industria Ticino Association
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*
Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)
FIT premia il miglior lavoro di diploma nella Tecnica dei sistemi chimico-farmaceutica della SSST
Progetto Talenti
Cultura e salute
Linkedin